GBS Inc. is a biosensor diagnostic technology company that operates in the Asia-Pacific and North America regions. The company offers Saliva Glucose Biosensor to measure glucose in saliva for diabetes management, and also focuses on developing SARS-CoV-2 Biosensor for virus detection. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests and is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.